You are here

Article Text

Article menu
Download PDFPDF
DTB select
Warning on use of ondansetron in first trimester of pregnancy

Abstract

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.

  • healthcare quality, access, and evaluation
  • primary healthcare

https://doi.org/10.1136/dtb.2020.000025

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Overview of European Medicines Agency Pharmacovigilance Risk Assessment Committee. Updated signal assessment report on birth defects following in-utero exposure during the first trimester of pregnancy arising from recent publications with ondansetron. EMA/PRAC/347675/2019

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.